{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:58:01Z","timestamp":1753891081797,"version":"3.41.2"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Idiopathic Inflammatory Myopathies are rare conditions with several heterogeneous disease subtypes. They can range from limited muscle or skin involvement to severe, systemic, life-threatening disease. Although the etiology is unknown, some evidence suggests a role for external agents, particularly drugs. Herein, we present a case of a 71-year-old woman with chronic myeloid leukemia who developed imatinib-induced dermatomyositis <jats:italic>sine dermatitis<\/jats:italic>. The presentation was predominantly muscular, characterized by proximal muscle weakness and myalgia of the lower limbs, with positive anti-Mi2a antibodies. Spontaneous recovery was observed after drug discontinuation, without the need for immunosuppressive therapy. This is the first confirmed description of an imatinib-induced dermatomyositis <jats:italic>sine dermatitis.<\/jats:italic> It reflects the importance of a high awareness from rheumatologists and hematologists to accurately anticipate and identify similar situations.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1398453","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T04:25:25Z","timestamp":1714364725000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Imatinib-induced dermatomyositis sine dermatitis - a rare case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Augusto","family":"Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasco C.","family":"Rom\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Campanilho-Marques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12194","article-title":"Diagnosis, pathogenesis and treatment of myositis: recent advances","volume":"175","author":"Carstens","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/imj.15358","article-title":"Idiopathic inflammatory myopathies: a review","volume":"51","author":"Ashton","year":"2021","journal-title":"Intern Med J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.55563\/clinexprheumatol\/jof6qn","article-title":"Idiopathic inflammatory myopathies: one year in review 2022","volume":"41","author":"Dourado","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.1309","article-title":"Dermatomyositis: Clinical features and pathogenesis","volume":"82","author":"DeWane","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.917801","article-title":"Myositis induced by isotretinoin: A case report and literature review","volume":"21","author":"Rivillas","year":"2020","journal-title":"Am J Case Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13346","article-title":"Rheumatic immune-related adverse events induced by immune checkpoint inhibitors","volume":"17","author":"Zhong","year":"2021","journal-title":"Asia Pac J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2006.02930.x","article-title":"Heliotrope-like eruption mimicking dermatomyositis in a patient treated with imatinib mesylate for chronic myeloid leukemia","volume":"45","author":"Kuwano","year":"2006","journal-title":"Int J Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/00131402-200403000-00002","article-title":"Inflammatory myopathy associated with imatinib mesylate therapy","volume":"5","author":"Srinivasan","year":"2004","journal-title":"J Clin Neuromuscul Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: an important tool to support diagnosis of myositis","volume":"280","author":"Betteridge","year":"2016","journal-title":"J Intern Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.53738\/REVMED.2015.11.456-57.0025","article-title":"Allergologie\u2013immunologie clinique. (3.) Nouveaux auto-anticorps dans les myopathies infammatoires et la scl\u00e9rose syst\u00e9mique [Novel autoantibodies in inflammatory myopathies and systemic sclerosis]","volume":"11","author":"Ribi","year":"2015","journal-title":"Rev Med Suisse"},{"key":"B11","article-title":"Principaux anticorps antinucl\u00e9aires et anticytoplasme au cours des polymyosites et des dermatomyosites. Etude de 42 observations [The principle antinuclear and anti-cytoplasmic antibodies in polymyositis and dermatomyositis. Study of 42 cases]","volume":"16","author":"Meyer","year":"1987","journal-title":"Presse Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.857030","article-title":"AC-X: characteristic antinuclear antibody patterns of two anti-mi-2 autoantibody-positive dermatomyositis patients-A case report","volume":"13","author":"Wu","year":"2022","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231168563","article-title":"Inclusion body myositis triggered with long-term imatinib use","author":"Deniz","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0443-7","article-title":"Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia","volume":"33","author":"Janssen","year":"2019","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.11.002","article-title":"Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec)","volume":"34","author":"Gordon","year":"2010","journal-title":"Leuk Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0708896","article-title":"Imatinib as a possible cause of severe rhabdomyolysis","volume":"358","author":"Penel","year":"2008","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1398453\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T04:25:27Z","timestamp":1714364727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1398453\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":16,"alternative-id":["10.3389\/fimmu.2024.1398453"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1398453","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2024,4,29]]},"article-number":"1398453"}}